StockData

Alvotech vs Immunocore

ALVO and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and IMCR compare

Immunocore grew revenue faster over the last twelve months (21.0% versus 19.7% for Alvotech).

Immunocore scores higher on the StockData Score (7 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVOIMCR
Size and price
Market cap–$1.4B
Share price$4.37$27.81
Change, 1 year−20.4%−22.6%
Change, 5 years−55.8%−23.6%
Beta (5Y)0.370.19
Employees1,000524
StockData Score
Total score37 (better)
Valuation score01 (better)
Growth score22
Performance score03 (better)
Health score11
Dividend score00
Valuation
P/S–3.3×
P/B–3.4×
FCF yield–−2.9%
Fair value–$32.29
Margin of safety–13.9%
Growth
Revenue growth (TTM)19.7%21.0% (better)
Revenue growth, 5Y average54.5%–
Profitability
Gross margin59.8%98.9% (better)
Operating margin13.3% (better)−5.2%
Net margin–−4.2%
FCF margin−19.6%−9.6% (better)
Return on equity–−4.5%
Financial health
Net debt / EBITDA10.02–
Interest coverage0.5× (better)−1.8×
Current ratio1.654.47 (better)
Altman Z-score–1.40
Piotroski F-score–3
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield–0.00%
Ownership
Held by institutions–102%
Held by insiders67.7%15.5%
Insider net buying, 12 months–−$1.9M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.